# Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

> **NCT01107522** · PHASE1 · UNKNOWN · sponsor: **Tactical Therapeutics, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas

## Interventions

- **DRUG:** CTO
- **DRUG:** CTO and Temodar®
- **DRUG:** CTO, Temodar®, Radiation therapy

## Key facts

- **NCT ID:** NCT01107522
- **Lead sponsor:** Tactical Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-05
- **Primary completion:** 2025-01
- **Final completion:** 2026-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01107522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01107522, "Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01107522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*